TY - JOUR
T1 - Insomnia
AU - Kutscher, Scott
AU - Juang, Christine
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Objective This article provides an overview of the current definitions, diagnostic tools, and overall management of insomnia. Latest Developments The treatment of insomnia has shifted over time, with a growing emphasis on nonpharmacologic therapies as a first-line intervention and the leveraging of technology to aid in the dissemination of these therapies. With this evolution, the definition of insomnia has changed to reflect a common treatment pathway. As pharmacologic treatment options have increased, so has concern about the dangerous short-term and long-term adverse effects of these treatment options. Essential Points Insomnia is a common disorder, frequently overlapping with other neurologic and psychiatric disorders, which can cause significant distress and disruption to patients' lives. Nonpharmacologic therapies are highly effective and are now considered first-line treatments. Although efficacy is variable, numerous pharmacologic interventions are available, and many options come with considerable concern about adverse effects, particularly in populations over 65 years old.
AB - Objective This article provides an overview of the current definitions, diagnostic tools, and overall management of insomnia. Latest Developments The treatment of insomnia has shifted over time, with a growing emphasis on nonpharmacologic therapies as a first-line intervention and the leveraging of technology to aid in the dissemination of these therapies. With this evolution, the definition of insomnia has changed to reflect a common treatment pathway. As pharmacologic treatment options have increased, so has concern about the dangerous short-term and long-term adverse effects of these treatment options. Essential Points Insomnia is a common disorder, frequently overlapping with other neurologic and psychiatric disorders, which can cause significant distress and disruption to patients' lives. Nonpharmacologic therapies are highly effective and are now considered first-line treatments. Although efficacy is variable, numerous pharmacologic interventions are available, and many options come with considerable concern about adverse effects, particularly in populations over 65 years old.
UR - http://www.scopus.com/inward/record.url?scp=85168267766&partnerID=8YFLogxK
U2 - 10.1212/CON.0000000000001283
DO - 10.1212/CON.0000000000001283
M3 - Review article
C2 - 37590828
AN - SCOPUS:85168267766
SN - 1080-2371
VL - 29
SP - 1167
EP - 1187
JO - CONTINUUM Lifelong Learning in Neurology
JF - CONTINUUM Lifelong Learning in Neurology
IS - 4
ER -